Mitotech sets sights on US dry eye market
This article was originally published in Scrip
Executive Summary
European, ophthalmology-focused biotech Mitotech is hoping positive results of a Phase II study for its dry eye product Visomitin (an ophthalmic formulation of SkQ1) will help the firm get a foothold in the US.